Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

June 4, 2024

https://www.globenewswire.com/news-release/2024/06/04/2893055/0/en/Silo-Pharma-Submits-Pre-Investigational-New-Drug-Application-to-FDA-for-SPC-15-as-a-Treatment-for-PTSD-and-Anxiety.html

Clinical roadmap unveiled for novel and proprietary intranasal PTSD treatment

SARASOTA, FL, June 04, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq:SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its submission of a pre-Investigational New Drug (pre-IND) briefing package and meeting request to the U.S. Food and Drug Administration (FDA) for SPC-15, Silo’s intranasal prophylactic treatment for post-traumatic stress disorder (PTSD) and stress-induced anxiety disorder.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.